$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

$fhtx Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009813 Filed on May 11, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2020 Q1
Revenue	$286.0K	$250.0K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.690M	$4.560M	$2.220M
YoY Change	111.26%
% of Gross Profit
Research & Development	$18.73M	$16.47M	$11.50M
YoY Change	62.79%
% of Gross Profit
Depreciation & Amortization	$800.0K	$570.0K	$300.0K
YoY Change	166.67%	42.5%
% of Gross Profit
Operating Expenses	$23.42M	$21.03M	$13.72M
YoY Change	70.62%
Operating Profit	-$23.13M		-$13.72M
YoY Change	68.54%
Interest Expense	$486.0K	-$320.0K	$258.0K
YoY Change	88.37%
% of Operating Profit
Other Income/Expense, Net	$144.0K	$560.0K	-$228.0K
YoY Change	-163.16%
Pretax Income	-$22.99M	-$20.76M	-$13.95M
YoY Change	64.8%
Income Tax
% Of Pretax Income
Net Earnings	-$23.00M	-$20.76M	-$13.95M
YoY Change	64.85%
Net Earnings / Revenue	-8041.96%	-8304.0%
Basic Earnings Per Share	-$0.62
Diluted Earnings Per Share	-$0.62	-$1.797M	-$2.709M
COMMON SHARES
Basic Shares Outstanding	36.82M shares	35.81M
Diluted Shares Outstanding	36.82M shares

Balance Sheet

Concept	2021 Q1	2020 Q4	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$160.9M	$185.8M
YoY Change		1140.04%
Cash & Equivalents	$66.45M	$92.80M	$3.443M
Short-Term Investments	$94.47M	$92.98M
Other Short-Term Assets	$4.400M	$4.900M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$165.3M	$190.7M
YoY Change		1029.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$61.20M	$19.53M
YoY Change		627.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.603M	$842.0K
YoY Change		7554.55%
Total Long-Term Assets	$64.57M	$64.91M
YoY Change		1089.43%
TOTAL ASSETS
Total Short-Term Assets	$165.3M	$190.7M
Total Long-Term Assets	$64.57M	$64.91M
Total Assets	$229.9M	$255.6M
YoY Change		1044.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.911M	$3.680M
YoY Change		7.01%
Accrued Expenses	$5.126M	$9.161M
YoY Change		147.53%
Deferred Revenue	$2.407M	$2.024M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$16.33M	$18.85M
YoY Change		48.96%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00M	$19.65M
YoY Change		79.32%
Other Long-Term Liabilities	$68.40M	$0.00
YoY Change
Total Long-Term Liabilities	$20.00M	$19.65M
YoY Change		79.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.33M	$18.85M
Total Long-Term Liabilities	$20.00M	$19.65M
Total Liabilities	$104.7M	$109.4M
YoY Change		359.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$185.9M	-$162.9M
YoY Change		73.09%
Common Stock	$4.000K	$4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$125.2M	$146.2M	-$101.2M
YoY Change
Total Liabilities & Shareholders Equity	$229.9M	$255.6M
YoY Change		1044.01%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2020 Q1
OPERATING ACTIVITIES
Net Income	-$23.00M	-$20.76M	-$13.95M
YoY Change	64.85%
Depreciation, Depletion And Amortization	$800.0K	$570.0K	$300.0K
YoY Change	166.67%	42.5%
Cash From Operating Activities	-$23.15M	-$10.66M	-$10.76M
YoY Change	115.08%	-58.16%
INVESTING ACTIVITIES
Capital Expenditures	$1.794M	-$7.490M	$1.021M
YoY Change	75.71%	4061.11%
Acquisitions
YoY Change
Other Investing Activities	-$1.470M	-$92.73M	$0.00
YoY Change
Cash From Investing Activities	-$3.261M	-$100.2M	-$1.021M
YoY Change	219.39%	58852.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$62.00K	128.5M	$247.0K
YoY Change	-74.9%	1387.38%
NET CHANGE
Cash From Operating Activities	-$23.15M	-10.66M	-$10.76M
Cash From Investing Activities	-$3.261M	-100.2M	-$1.021M
Cash From Financing Activities	$62.00K	128.5M	$247.0K
Net Change In Cash	-$26.35M	17.63M	-$11.54M
YoY Change	128.38%	-203.64%
FREE CASH FLOW
Cash From Operating Activities	-$23.15M	-$10.66M	-$10.76M
Capital Expenditures	$1.794M	-$7.490M	$1.021M
Free Cash Flow	-$24.94M	-$3.170M	-$11.78M
YoY Change	111.67%	-87.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001822462
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-39634
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Foghorn Therapeutics Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5271393
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Technology Square, Ste 700
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2021Q1	dei	City Area Code CityAreaCode	617
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	586-3100
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	FHTX
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36846084	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66449000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92795000	USD
CY2021Q1	us-gaap	Marketable Securities MarketableSecurities	94468000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	92975000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4398000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4917000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	165315000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	190687000	USD
CY2021Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19493000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19528000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1603000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41742000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42804000	USD
CY2021Q1	us-gaap	Assets Assets	229886000	USD
CY2020Q4	us-gaap	Assets Assets	255594000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2911000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3680000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5126000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9161000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5783000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3981000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2407000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2024000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16332000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18846000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	19739000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	19654000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56548000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58361000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	225000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11878000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12546000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	104722000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	109407000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36826775	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36826775	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790946	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36790946	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	311076000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	309126000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185922000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162936000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	125164000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	229886000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	255594000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	286000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18726000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11503000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4690000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2221000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	23416000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	13724000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23130000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13724000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	486000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	258000	USD
CY2021Q1	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	630000	USD
CY2020Q1	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	29000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-228000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22986000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13952000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.71
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36817277	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5154229	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22986000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13952000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	13000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22973000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13952000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1888000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	13000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22986000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	125164000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-88016000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	247000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	517000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13952000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-101204000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22986000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-13952000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1888000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	517000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	772000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	255000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	USD
CY2021Q1	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	1062000	USD
CY2020Q1	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	608000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	85000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	64000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	13000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	295000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	64000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-754000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	969000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26467000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	25000000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2609000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17000	USD
CY2021Q1	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-11000	USD
CY2020Q1	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	859000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-286000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23147000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10762000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1794000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1021000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3261000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1021000	USD
CY2020Q1	us-gaap	Restricted Cash RestrictedCash	2276000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	62000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	247000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	247000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-26346000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-11536000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17255000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68182000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5719000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	400000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	190000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	959000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1471000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66449000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3443000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	1733000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68182000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5719000	USD
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000.0	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185900000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	94463000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	94468000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	92982000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	92975000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	384000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	USD
CY2021Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	22368000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	21631000	USD
CY2021Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2875000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2103000	USD
CY2021Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19493000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19528000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	978000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3513000	USD
CY2021Q1	fhtx	Accrued Tenant Improvements AccruedTenantImprovements	913000	USD
CY2020Q4	fhtx	Accrued Tenant Improvements AccruedTenantImprovements	2385000	USD
CY2021Q1	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2477000	USD
CY2020Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2146000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	620000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	979000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	138000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	138000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5126000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9161000	USD
CY2021Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000	USD
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20000000	USD
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	1000000	USD
CY2020Q4	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	1000000	USD
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1261000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1346000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	19739000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	19654000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	833000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10000000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9167000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20000000	USD
CY2021Q1	fhtx	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6321699	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19936239	shares
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1888000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	517000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	26300000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M18D
CY2021Q1	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000.0	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15000000.0	USD
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14300000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1887000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1258000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	27000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	763000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	236000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	2650000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	1521000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2371000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	456000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	38306000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	330000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	78990000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	7391000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10005000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10115000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10355000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10603000	USD
CY2021Q1	fhtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	30521000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14261000	USD
CY2021Q1	fhtx	Lessee Operating Lease Liability Estimated Lease Incentives LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives	2398000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	62331000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5783000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56548000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	62331000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2600000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	600000	USD
CY2021Q1	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2021Q1	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	400000	USD
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	300000	USD

Files In Submission

Name	View Source	Status
0001628280-21-009813-index-headers.html	Edgar Link	pending
0001628280-21-009813-index.html	Edgar Link	pending
0001628280-21-009813.txt	Edgar Link	pending
0001628280-21-009813-xbrl.zip	Edgar Link	pending
fhtx-20210331.htm	Edgar Link	pending
fhtx-20210331.xsd	Edgar Link	pending
fhtx-20210331xex311.htm	Edgar Link	pending
fhtx-20210331xex312.htm	Edgar Link	pending
fhtx-20210331xex321.htm	Edgar Link	pending
fhtx-20210331xex322.htm	Edgar Link	pending
fhtx-20210331_cal.xml	Edgar Link	unprocessable
fhtx-20210331_def.xml	Edgar Link	unprocessable
fhtx-20210331_htm.xml	Edgar Link	completed
fhtx-20210331_lab.xml	Edgar Link	unprocessable
fhtx-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

2021 Q1 Form 10-Q Financial Statement

#000162828021009813 Filed on May 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX Foghorn Therapeutics Inc. Stock $fhtx

2021 Q1 Form 10-Q Financial Statement

#000162828021009813 Filed on May 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx